Ownership and insider activity for Eledon Pharmaceuticals, Inc. (ELDN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells.
Price
| Price | $2.67 |
| Market Cap | $206M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $23.2M | $17.2M | $13.0M | $8.8M | $114.2M | $84.8M | $56.4M | $4.6M | $20.5M | $22.8M |
| Short-term Investments | $4.2M | 0 | 0 | 0 | 0 | 0 | 0 | $46.5M | $119.6M | $110.5M |
| Receivables | 0 | 0 | $594000 | $245000 | $110000 | 0 | 0 | 0 | 0 | $514000 |
| Inventory | 0 | 0 | 0 | $881000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $29.5M | $19.0M | $14.3M | $10.0M | $115.6M | $88.3M | $59.5M | $56.1M | $143.7M | $135.7M |
| Property, Plant & Equipment | $98000 | $25000 | $14000 | $321000 | $138000 | $768000 | $739000 | $365000 | $926000 | $613000 |
| Goodwill | 0 | $1.9M | $1.9M | 0 | $48.6M | $48.6M | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | $32.4M | $32.4M | $32.4M | $32.4M | $32.4M | $32.4M |
| Total Assets | $29.8M | $20.9M | $17.0M | $10.9M | $197.2M | $170.5M | $92.8M | $89.1M | $177.4M | $169.0M |
| Accounts Payable | $338000 | $418000 | $689000 | $329000 | $1.4M | $1.8M | $2.2M | $967000 | $5.8M | $3.6M |
| Short-term Debt | $3.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.8M | $1.4M | $2.5M | $1.3M | $2.5M | $4.4M | $6.5M | $3.9M | $11.6M | $18.3M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $2.9M | $1.4M | $2.5M | $1.5M | $6.6M | $6.6M | $8.6M | $81.9M | $59.3M | $87.9M |
| Retained Earnings | -$169.4M | -$27.5M | -$41.6M | -$57.6M | -$80.4M | -$114.9M | -$202.9M | -$319.4M | -$355.6M | -$401.2M |
| Total Equity | $26.9M | $19.5M | $14.5M | $9.5M | $190.6M | $164.0M | $84.2M | $7.2M | $118.1M | $81.1M |
| Total Debt | $3.4M | 0 | 0 | $324000 | $144000 | $769000 | $746000 | $383000 | $954000 | $641000 |
| Net Debt | -$24.0M | -$17.2M | -$13.0M | -$8.5M | -$114.1M | -$84.1M | -$55.7M | -$50.7M | -$139.2M | -$132.7M |
| Working Capital | $26.7M | $17.6M | $11.7M | $8.6M | $113.1M | $83.9M | $53.0M | $52.2M | $132.2M | $117.3M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 7.90 |
Profitability
| Return on Equity | -136.45% |
| Return on Invested Capital | -73.77% |
| Return on Assets | -78.16% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABEO · ACHV · ALLO · AVIR · EDIT · HUMA · PBYI
Explore sector: Healthcare · Biotechnology
More sections of ELDN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks